PUBLISHER: Grand View Research | PRODUCT CODE: 1751299
PUBLISHER: Grand View Research | PRODUCT CODE: 1751299
The global cardiac biomarkers market is anticipated to reach USD 51.19 billion by 2030 and is anticipated to expand at a CAGR of 14.1% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of acute coronary syndrome (ACS), along with advancements in biomarker technologies, is expected to propel market growth. The rising awareness regarding early diagnosis and prognosis of cardiac diseases is expected to further drive the market.
According to the report by Cleveland Clinic, more than 18 million adults in the U.S. were affected by coronary heart disease. Chest pain is one of the most common reasons for emergency department visits. Heart disease is one of the major causes of death in the U.S., and it is estimated that a person has a heart attack every 41 seconds. Cardiac biomarkers play a significant role in ACS diagnosis and facilitate faster treatment decision-making, thereby making them crucial.
The rising adoption of biomarkers in risk stratification and diagnosis of acute coronary syndrome is increasing the demand. An unhealthy lifestyle is driving the prevalence of acute coronary syndrome and myocardial infarction. The increasing adoption of PoC diagnostics is driving segment innovation, making the use of cardiac markers easier. The paradigm shift in the adoption of cardiac biomarkers in hospitals and PoC settings can be attributed to the recent developments in assays pertaining to the sensitivity of cardiac troponin I and cardiac troponin.